Volume 24, Number 1—January 2018
Research Letter
Whole-Genome Analysis of Recurrent Staphylococcus aureus t571/ST398 Infection in Farmer, Iowa, USA
Table
Date | Antimicrobial drug resistance profile | Description of infection | Treatment |
---|---|---|---|
July 2011 |
TET, SXT, LVX |
Cellulitis |
Ciprofloxacin |
November 2011 |
TET, SXT, LVX |
Cellulitis, draining pus, headache, ill feeling |
Ciprofloxacin, Neosporin, warm compress, incision, drainage |
August 2012† | TET, SXT, LEVO (isolate 1); OXA, TET, SXT, LVX (isolate 2) | None provided | Mupirocin, SXT, ciprofloxacin, warm compress, drainage |
*All isolates were t571/ST398 and were PVL negative. Neosporin is manufactured by Johnson & Johnson (New Brunswick, NJ, USA). LEVO, levofloxacin; LVX, levofloxacin resistance to isolate 2; OXA, oxacillin; SXT, trimethoprim/sulfamethoxazole; TET, tetracycline.
†Two isolates from this infection were tested and had different antimicrobial drug resistance profiles as noted.
Page created: December 19, 2017
Page updated: December 19, 2017
Page reviewed: December 19, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.